Glenmark Pharmaceuticals USA launches Clindamycin Phosphate Foam, 1%

Glenmark’s Clindamycin Phosphate Foam, 1% is bioequivalent and therapeutically equivalent to Evoclin Foam, 1%, of Mylan Pharmaceuticals.

Glenmark Pharmaceuticals USA (Glenmark) announces the launch of Clindamycin Phosphate Foam, 1%.

Glenmark’s Clindamycin Phosphate Foam, 1% is bioequivalent and therapeutically equivalent to the reference listed drug, Evoclin Foam, 1%, of Mylan Pharmaceuticals.

According to IQVIATM sales data for the 12-month period ending December 2024, the Evoclin Foam, 1% market achieved annual sales of approximately $5.8 million.